MAOLATE
LOE Approachingchlorphenesin carbamate
NDAORALTABLET
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAOLATE (chlorphenesin carbamate) is an oral muscle relaxant tablet approved in 1965 for symptomatic relief of acute musculoskeletal conditions. The drug works as a central-acting skeletal muscle relaxant, though its precise mechanism of action is not fully characterized in available data. It is indicated for patients experiencing muscle spasms and related pain from injury or musculoskeletal disorders.
LOE Approaching
With LOE approaching, the brand team is likely in defensive mode, focused on retention and managed care negotiations rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAOLATE offers limited career growth potential due to its LOE-approaching status and minimal linked job openings. Professionals on this brand typically gain expertise in defensive commercial strategies, managed care negotiation, and generic erosion mitigation—skills valuable in legacy product portfolios but not aligned with innovation-focused career trajectories.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.